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Homocysteine is an amino acid that is toxic to vascular endothelial cells, and plasma elevations have been associated
with venous thromboembolism. Severe hyperhomocysteinemia (>100 μmol/L) may result from mutations in the genes
coding for enzymes in the trans-sulfuration or the folate/vitamin B12-dependent re-methylation pathways. Here, we
report the case of a young woman with severe, recurrent thrombo-embolic events associated with severe
hyperhomocysteinemia (111 μmol/L). We identified a homozygous mutation in the cystathionine β -synthase gene
(p.I278T) and the presence of the Factor V Leiden mutation. Family study shows segregation of elevated homocysteine
in heterozygous relatives for the mutation in the cystathionine β -synthase gene. Management consisted of
anticoagulation with warfarin and supplementation with folate, vitamin B6 (pyridoxine) and vitamin B12. After twelve
years of follow-up, plasma homocysteine levels remain in the moderate range (~20 μmol/L, reference range 8-12 μmol/L)
and no further thromboembolic events were identified.Introduction
Elevated free and protein-bond plasma homocysteine
(tHcy) has been associated with venous thrombosis, pul-
monary embolism and premature mortality. Methionine
is a major donor of a methyl group required for a large
variety of biological molecules and the resultant mol-
ecule, homocysteine, is toxic to vascular endothelial tis-
sues. Homocysteine can be metabolized through the
trans-sulfuration pathway. The enzyme cystathionine
β-synthase (CBS) (EC 4.2.1.22) catalyses the condensation
of homocysteine and serine to yield cystathionine, a reac-
tion requiring pyridoxine (vitamin B6) as a cofactor. Cysta-
thionine γ-lyase (EC 4.2.1.22) then converts cystathionine
to cysteine and α-ketobutyrate. Alternatively, homocyst-
eine can be recycled into methionine through the folate
pathway. This process uses N5-methyltetrahydrofolate,
S-Adenosylmethionine and methylcobalamin, with meth-
ylenetetrahydrofolate reductase (MTHFR) (EC 1.5.7.1) as* Correspondence: jacques.genest@mcgill.ca
2The McGill University Health Centre, Montreal, Canada
5Royal Victoria Hospital, 687 Pine Avenue West, Rm M4.72, Montreal, QC H3A
1A1, Canada
Full list of author information is available at the end of the article
© 2014 Awan et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the rate-limiting step [1]. Median plasma levels of tHcy
levels in Western populations are 10 to 12 μmol/L with
women having 10-15% lower homocysteine levels during
their reproductive years.Case presentation
Here, we present a 30-year follow up on a woman with re-
current venous thromboembolism associated with both
severe hyperhomocysteinemia, and the Factor V Leiden
(FVL) mutation.
At the age of 21, a woman was referred to our institu-
tion with severe headache, nausea and vomiting. A CT
scan of the head and lumbar puncture were not diagnos-
tic. A diagnosis of a viral infection was made. While
traveling abroad, her symptoms reappeared and were as-
sociated with decreased level of consciousness. On admis-
sion, a CT scan showed a hypo-dense lesion in the left
thalamus, with no hydrocephalus or mass lesion. All cul-
tures were negative and a presumptive diagnosis of viral
infection was again made. The patient was started on
acyclovir, a cephalosporin, and dexamethasone. The symp-
toms were alleviated and the patient was discharged.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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symptoms and loss of consciousness. On examination
she was afebrile, had a blood pressure of 140/75, and the
Glasgow coma scale score was 12 (moderate impair-
ment; control is 15). She was noted to have roving eye
movements, and disc margins were blurred on the nasal
fields. Cranial nerves were intact. Hand grasp was weaker
on the right side than on the left; the right upper limb was
hyperreflexic. An angiogram showed occlusion of the
intra-cerebral veins supplying the head of caudate. This
was thought to be due to a thrombotic event. She was
continued on steroid treatment and was discharged after
her symptoms were stabilized. She was not put on sys-
temic anticoagulation at that time.
At the age of 28, she had pre-eclampsia. She was treated
with bisoprolol for post-partum hypertension. She devel-
oped thrombophlebitis at the age of 34 (Figure 1). At
follow up, an MRI showed old hemorrhagic foci in the an-
terior limb of the left internal capsule, both thalami, and
the left posterior superior frontal lobe.
Laboratory results showed levels of protein C and S
within the reference ranges, and negative phospholipid
antibodies. She was found to be heterozygous for the FVL
mutation. Her tHcy level preceding her thrombophlebitis
event was 54 μmol/L, and increased to 111 μmol/L within
one year (reference range 4.6-15.5 μmol/L) (Figure 1 and
Table 1). Plasma levels of vitamin B12, Folate and red
blood cell folate were within reference ranges. Daily one
time oral supplements of Vitamins B12 (1000 μg), vitamin
B6 (100 mg), and folate (5 mg) were started, and later
betaine (750 mg/kg) was added; her tHcy levels decreased
to approximately 15-20 μmol/L.
The remainder of the investigations was within the ref-
erence range. Protein C and S, Lipoprotein (a), anticar-
diolipin antibodies and antithrombin III levels wereFigure 1 Clinical course of index proband over 30 years. The initial prese
accident (CVA) led to further investigations. The patient was found to have ve
Treatment with warfarin and folate, vitamin B12 and vitamin B6 resulted in a d
thrombo-embolic phenomena were observed.within normal. Prothrombin gene mutation (20210) was
negative.
Her father had a history of a myocardial infarction at the
age 50. Neither the patient nor her family members have a
Marfanoid habitus, nor joint hyperlaxity or other skeletal
anomalies. They do not have lens dislocations or mental re-
tardation. The tHcy level was moderately elevated in both
parents. Her mother was heterozygous for FVL mutation.
We performed a skin biopsy and cultured skin fibro-
blasts to examine known inborn error of cobalamin me-
tabolism. The incorporation of both [14C]-propionate and
[14C]-methyltetrahydrofolate and the uptake of [57Co]-
cyanocobalamin were normal. The proband had adequate
synthesis of both adenosylcobalamin and methylcobala-
min. We used a targeted gene sequencing approach to
identify the molecular defect. The MTHFR gene (OMIM
236250) was sequenced and the common 677C > T poly-
morphism was found in 4 of 9 family members, although
not in the proband (Figure 1). We subsequently sequenced
the cystathionine β-synthase gene (OMIM 236200). The
proband had a homozygous (p.I278T) mutation in the
CBS gene, a known vitamin B6-responsive mutation [2-4].
In addition to this deleterious mutation at the CBS gene,
the patient had coagulation FVL, a combination of find-
ings traits shared by no other family members (Figure 2).
The management of the patient includes folic acid, vita-
min B12 and vitamin B6 as described above, warfarin,
targeting an international normalized ratio of 2.0-2.5, a
beta-adrenergic blocker for hypertension, and a statin for
elevated cholesterol. The patient has remained asymptom-
atic for nearly twelve years.
Discussion
Homocysteine promotes vascular disease in part by caus-
ing endothelial cell dysfunction and reduced thrombolysisntation of cerebral thrombosis, thrombophlebitis and cerebrovascular
ry elevated total homocysteine (tHcy) levels and Factor V Leiden.
ramatic reduction of tHcy. Over a 12-year follow-up period, no further
Table 1 Demographic characteristics and investigation results for the proband and her family
ID Gender Age Total cholesterol LDL tHcy CBS MTHFR FVL
102 F 89 5.85 3.86 9.1 + / - + / - - / -
201 M 66 3.12 2.07 18.1 + / - - / - - / -
202 F 67 6.11 4.04 19.3 + / - + / - + / -
301 (Proband) F 41 4.77 3.07 111 + / + - / - + / -
303 M 43 6.02 4.26 18.4 - + / - - / -
401 M 13 3.14 1.75 11.4 - + / - + / -
412 F 12 4.72 3.31 8.4 - - / - - / -
410 F 6 5.16 3.57 8.1 - - / - - / -
ID: number refers to Figure 2, LDL: low density lipoprotien cholesterol, tHcy: total homocysteine, CBS: cystathionine β-synthase gene mutation (p.I278T),
MTHFR: methylenetetra-hydrofolate reductase C766T single nucleotide polymorphism, FVL: Factor V Leiden mutation.
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tation was associated with 25% reduction in homocysteine
level but has no effect on vascular outcomes or all-cause
mortality. Resistance to activated protein C, typically due
to the FVL mutation, is the most common inherited cause
of sporadic thrombosis [7]. Thromboembolism occurs in
only about one third of patients with homocystinuria,
which suggests that other contributory factors are needed
for the development of thrombosis. Screening for FVL
may be indicated in patients with homocystinuria andFigure 2 Kindred showing index patient (301) and her family. Note ho
co-existant Factor V Leiden.their family members [8]. In a study on 24 patients with
hyperhomocysteinemia due to CBS deficiency, six patients
had a thrombotic event, only one was a carrier for FVL
and three were carrier of MTHFR 677C > T mutation.
These and additional data from Ireland, indicate that FVL
is not an absolute determinant of venous thrombosis in
homocystinuria caused by CBS mutations [9].
In a large cohort analysis of 19,678 patients with ven-
ous thrombosis who underwent thrombophilia screening
in Italy, 38 had severe hyperhomocysteinemia (0.2%). Inmozygosity for the cystathionine beta-synthase gene I278T and
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(range 19-83), and the median level of tHcy was 130 μmol/L
(range 101-262). Recurrent thrombosis occurred in 42% of
cases [10]. In seven families in a consanguinous Israeli
Arab population, 4/45 members were both homozygous
for CBS and heterozygous for the FVL mutation, and all
four developed deep vein thrombosis. The increased ten-
dency to thrombosis could result from an additive adverse
effect of these two defects on a common protective mech-
anism in the coagulation cascade. The authors concluded
that major thrombotic events occurred only in concurrent
homocystinuria and FVL mutations, as is seen in our pa-
tient [11]. In a Turkish study, one out of six subjects with
CBS mutation had.
FVL and developed severe thrombosis leading to am-
putation of the leg [12]. A study from Italy showed a
mutation of CBS gene associated with FVL mutation
causes severe deep vein thrombosis despite only mild
elevation of the homocysteine level [9]. Consistent with
this study, our patient had moderate to severe homocys-
teinemia and suffered multiple thrombotic events. There
is an association between serum homocysteine and pre-
eclampsia consistent with the increase risk of vascular
damage and thrombosis. One study that included fifty
pregnant women with preeclampsia, found that 54%
have hyperhomocysteinemia caused by low vitamin B12
and folate [13].
Our patient has recurrent thromboembolic episodes.
In line with current guideline, lifelong anticoagulant is
warranted. However, since the severe hyperhomocystei-
nemia is corrected the question whether anticoagulant
can be stopped needs to be discussed with the patient.
Homocysteine is also associated with arterial occlusive
disease, but this association has been in great part ex-
plained by co-variables, such as renal function, male
gender and increasing age. In a multi-variate analysis,
homocysteine does not appear to be a strong cardiovascu-
lar risk factor [14-17]. Clinical trials aimed at preventing
cardiovascular diseases have failed to show a reduction in
cardiovascular events, and the interest for measuring
homocysteine has fallen dramatically. It is not surprising,
therefore, that sporadic cases such as the one presented
here can have such a dramatic presentation, untreated for
many years [11,16,18]. An index of suspicion therefore
should alert physicians to measure plasma tHcy levels in
unexplained venous thrombo-embolic events. The re-
sponse to treatment in this case had likely contributed to
the patient’s satisfactory clinical evolution over the past
twelve years.
Conclusion
When tHcy levels are consistently very high, evaluation of
family members is important, starting with siblings and
parents. Some authorities strongly argue that a moleculardiagnosis is required as this knowledge may change the
therapeutic approach.
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